| Drug Type Chemical drugs | 
| Synonyms- | 
| Target | 
| Action antagonists | 
| Mechanism BMPR2 antagonists(Bone morphogenetic protein receptor type-2 antagonists) | 
| Therapeutic Areas | 
| Active Indication | 
| Inactive Indication- | 
| Originator Organization | 
| Active Organization | 
| Inactive Organization- | 
| License Organization- | 
| Drug Highest PhasePreclinical | 
| First Approval Date- | 
| Regulation- | 
| Indication | Highest Phase | Country/Location | Organization | Date | 
|---|---|---|---|---|
| Leukemia | Preclinical | United States  | 28 Apr 2025 | |
| Small Cell Lung Cancer | Preclinical | United States  | 28 Apr 2025 | 





